Professor Roy Fleischmann, Rheumatologist, University of Texas Southwestern Medical Center at Dallas, TX, US
Can you explain the rationale and aim of SELECT-COMPARE?
Can you describe participant characteristics of note?
Can you describe the study design, including endpoints?
What did the results show?
What’s next for upadacitinib in patients with rheumatoid arthritis?
Top image: © stockdevil
The content and interpretation of these conference highlights are the views and comments of the speakers / authors.